Preeclamptic Patients and Pentraxin 3 & Lipoprotein-associated Phospholipase A2

CompletedOBSERVATIONAL
Enrollment

80

Participants

Timeline

Start Date

January 20, 2020

Primary Completion Date

May 20, 2020

Study Completion Date

May 20, 2020

Conditions
Pre-Eclampsia
Interventions
DIAGNOSTIC_TEST

Pentraxin 3 ; new biomarker

"Pentraxin (PTX3) is an inflammatory molecule that belongs to a recently identified, well-known C-reactive protein (CRP) family.~PTX3 plasma levels increase in vascular disorders including myocardial infarction and correlate with small vessel vasculitis and outcome or disease activity.~These biological and clinical features of PTX3 have led us to investigate this molecule in preeclampsia, a syndrome characterized by a prominent vascular component."

DIAGNOSTIC_TEST

Lipoprotein-associated phospholipase A2 ; new biomarker

Lp-PLA2 is a recently described and potentially useful plasma biomarker associated with cardiovascular diseases. Because of this effect, we will investigate that preeclampsia also be beneficial.

Trial Locations (1)

33404

Kanuni Sultan Süleyman Training and Research Hospital, Istanbul

All Listed Sponsors
lead

Kanuni Sultan Suleyman Training and Research Hospital

OTHER

NCT04239352 - Preeclamptic Patients and Pentraxin 3 & Lipoprotein-associated Phospholipase A2 | Biotech Hunter | Biotech Hunter